Royalty Pharma plc (NASDAQ:RPRX – Get Rating) Director Mario Germano Giuliani sold 261,881 shares of the stock in a transaction that occurred on Wednesday, September 7th. The shares were sold at an average price of $42.66, for a total transaction of $11,171,843.46. Following the completion of the sale, the director now directly owns 8,814,759 shares of the company’s stock, valued at approximately $376,037,618.94. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Mario Germano Giuliani also recently made the following trade(s):
- On Thursday, August 25th, Mario Germano Giuliani sold 500 shares of Royalty Pharma stock. The stock was sold at an average price of $44.00, for a total transaction of $22,000.00.
Royalty Pharma Price Performance
Shares of RPRX opened at $43.63 on Friday. Royalty Pharma plc has a twelve month low of $34.86 and a twelve month high of $44.75. The firm’s fifty day simple moving average is $43.13 and its 200-day simple moving average is $41.29. The firm has a market capitalization of $26.49 billion, a price-to-earnings ratio of 56.66, a PEG ratio of 1.14 and a beta of 0.30. The company has a current ratio of 19.22, a quick ratio of 19.22 and a debt-to-equity ratio of 0.68.
Royalty Pharma Announces Dividend
Institutional Investors Weigh In On Royalty Pharma
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Signaturefd LLC raised its stake in Royalty Pharma by 53.9% during the 1st quarter. Signaturefd LLC now owns 688 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 241 shares in the last quarter. Captrust Financial Advisors raised its stake in Royalty Pharma by 210.8% during the 2nd quarter. Captrust Financial Advisors now owns 805 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 546 shares in the last quarter. Newfound Research LLC acquired a new stake in Royalty Pharma during the 2nd quarter worth $50,000. PNC Financial Services Group Inc. raised its stake in Royalty Pharma by 54.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,423 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 1,208 shares in the last quarter. Finally, Gladius Capital Management LP acquired a new stake in Royalty Pharma during the 1st quarter worth $143,000. 54.94% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities analysts have commented on the stock. Morgan Stanley raised their price target on shares of Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a research report on Monday, August 8th. Tigress Financial raised their price target on shares of Royalty Pharma from $52.00 to $57.00 and gave the company a “buy” rating in a research report on Thursday, July 14th. Citigroup raised their price target on shares of Royalty Pharma from $50.00 to $60.00 in a research report on Thursday, July 28th. Scotiabank assumed coverage on shares of Royalty Pharma in a research report on Friday, May 13th. They issued an “outperform” rating and a $53.00 price target for the company. Finally, UBS Group assumed coverage on shares of Royalty Pharma in a research report on Monday, June 13th. They issued a “buy” rating and a $47.00 price target for the company. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $53.43.
Royalty Pharma Company Profile
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
- Get a free copy of the StockNews.com research report on Royalty Pharma (RPRX)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.